Zontivity

Chemical Namevorapaxar
Dosage FormTablet (oral; 2.08 mg)
Drug ClassReceptor antagonists
SystemCardiovascular
CompanyXspire Pharmaceuticals
Approval Year2014

Indication

  • Indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).
Last updated on 7/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zontivity (vorapaxar) Prescribing Information. 2019Xspire Pharmaceuticals LLC, Madison, MS